Here's the juice on MAMH
Took it directly from the MAMH thread
Lurking has it's advantages, but that was then.
Read the goods, read the thread, do what you have to do, but respond!!
CJW
MAMMATECH CORP (OTC BB: MAMH)
Recent Price: $0.027/share
Daily Average Volume: 620 K
97 EPS: $0.0014/share
97 PE: 19.3
Estimated 1998 EPS:$0.05/share
98' PE: 0.54
Div/Shr: None
Yield: None
52-week Range: $0.001-0.04/share
Outstanding Shares: 100.352 M
Floating Shares: 44.03 M
1997 revenues: $0.438 M
Estimated 1998 revenues: $20 M
Profit margin: 30-40%
SEC failings: Yes
BUSINESS SUMMARY AND CORPORATION BACKGROUND: The Company owns all rights to and is engaged in the sale of a patented breast tumor detection training system (the "MammaCare System"). Using lifelike models of a human female breast, the MammaCare System is designed to train women to perform effective Breast Self-Examination. The breast models contain simulated tumors of varying sizes, ranging from under 5mm. to over 10mm. They also contain material which simulates the normal modularity, or "lumpiness", that characterizes most breast tissue.
Although the patient can never determine whether a lump is benign or malignant, detection of tumors in the size range simulated by the models is important to early diagnosis of malignancies. Thus, by training women to palpate the breast model (and their own breasts) properly, the MammaCare System will lead to early detection of breast cancer and thus reduce morbidity and mortality due to this disease. Competent monthly breast self-examination is one of the best protections against breast cancer. It is now known that many breast cancers detected early enough can be treated by simply removing the tumor along with a narrow margin of healthy tissue. In fact, breast cancer is generally among the easiest cancers to find at an early stage. Since breast is an external and soft part of your body, it is possible to detect a tumor with your fingers, even when it is still hardly larger than a pea.
The MammaCare System is sold in several forms, all of which contain at least one of the Company's patented breast models. Originally, a client was given private training after which she was provided with a take-home breast model and other materials. Now, the customer may view a video tape developed by the Company which teaches her the proper use of the model(s) and an extremely thorough examination technique. The practice model is designed to permit a woman to reinforce her lump detection skills periodically and serves as a comparative standard as she palpates her own breast.
The MammaCare System and the MammaCare Learning Systems are each sold as an integrated whole. The Company does not permit models to be sold separately without each woman receiving appropriate training, either through the actual training sessions required in connection with the MammaCare System, through the video training contained in either of the Learning Systems, or through training provided by the Arkansas, California, Florida, and Maine Divisions of the American Cancer Society in accordance with the Company's standards.
RECENT DEVELOPMENTS AND ANALYSIS: During last fiscal year, the Company has intensified its efforts to offer MammaCare overseas. To date, the Company has marketed its products in Australia, Japan, Korea, France, Germany, Denmark, and Western Europe. Also, the Company has developed an extensive customer base in Canada and anticipates increased activity in that country as the trade barriers continue to be dismantled as a result of NAFTA. The Company has trained a number of MammaCare Specialists who live and work in Canada and maintains close professional ties to these individuals.
Women often are told the chance of getting breast cancer is 1 in 8. This means that from birth until age 90 the chance of being diagnosed with breast cancer is 1 in 8. The chance of getting breast cancer increases as women get older. The chance that any woman will die of invasive breast cancer 2 % (about 1 of every 50 women). Currently, mammograms are the most popular way to detect breast cancer. The use of mamograms carries certain risk due to the exposure of X- ray and expensive. In many countries, Mamograms are not available to all women. Thus, alternative screening for breast cancers are urgently needed. The MammaCare Method is no substitute for periodic professional exams and mammography. But for Breast Self-Examination, MammaCare is best. The 2-page article on MammaCare appeared in the premier issue of Be Well, a special magazine devoted to women's health issues and published by Family Circle. Readers are invited to take advantage of a discount offer in purchas!
!
ing the Company's Personal Learning System. Also, MAMH distributes its MammaCare products via the Internet at mammacare.com.
In September 1997, MAMH was awarded a Phase II grant in the amount of $592,000 from the Small Business Innovative Research (SBIR) Program of the National Institutes of Health (NIH). These funds will be expended over a two year period to determine if the two variations of its MammaCare Personal Learning System, one for visually impaired women and one for the hearing impaired, will be acceptable for home use by women in these populations. NIH rarely gives these awards to a private company for developing commercial products unless the products have significant importance in improvement of woman health. This award suggests MammaCare techniques have a huge potential in its application in early detection of breast cancer. The University of North Carolina at Chapel Hill has received a federal grant to train all of its residents and staff physicians in the MammaCare Method. The Company estimates that it will receive approximately $10,000 for the sale of breast models and cons!
!
ulting fees. In addition, the University of North Carolina has received a separate $1,117,992 grant which will involve the training of approximately 200 local physicians to upgrade the quality of clinical breast screening in the greater Wilmington area. In addition to mammography, this project will also involve the Company's patented MammaCare System. This project is currently in its final phase and is results should be available soon. The Company also continued its efforts to broaden the availability of MammaCare throughout the medical community. Toward this end, seven additional MammaCare Specialists were trained and certified. These individuals represent such diverse groups as The Fox Chase Cancer Center, the Breast and Cervical Cancer Program of various states supported by the Center for Disease Control (CDC), and the Zeneca Corporation.
Other institutions and organizations conducting research involving MammaCare include Johns Hopkins University, the Fred Hutchinson Cancer Center, the University of California at San Diego, the University of Oregon, the University of Arkansas, the University of Vermont, the State University of New York at Stony Brook, the Harvard Community Health Plan, the University of Cincinnati, the University of Indiana, the Fox Chase Cancer Center, Northwestern University, the University of West Virginia and U.S. Healthcare.
MAMH shares have been traded very actively since last month, suggesting there is growing genuine interests in MAMH among investors. This morning we just learned that the company has signed a sale and distribution agreement with a company in Germany. The sale revenues will be about $13-15 million in first 6 months. Also, the company is in the final stage of negotiation with a Japanese company and a Korean company for exclusive distribution rights of MammaCare system in Japan and Korea. The sale revenues will be about $5 million in first six months. The US and Canada sale revenues are projected about $2 M for next 6 months. The company has been profitable and its outstanding shares have not been changed in the past three years. The gross profit is unusual high at 75%, because MAMH has unique technology and just needs to sell MammaCare products more in the market. In addition, we heard a rumor that Merck may buy MAMH out. We will try to confirm this rumor later on. Wit!
!
h these recent developments, the target price for MAMH shares is in a range of $0.10 to $0.20 in a short term and is in a range of $0.40-0.50 in a long term.
Contact:
Mary B. Sellers
930 N.W. 8th Avenue,
Gainesville, Florida 32601
Tel (352) 375-0607
Fax (352) 375-6111
E-Mail: info@mammacare.com
Company Website: mammacare.com
---------------------------------- |
